Compounds that inhibit MCL-1 protein

US11306107B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Sean P. Brown · Craydon Court, US
• David Karl Bedke · Dodgeville, US
• Michael R. DeGraffenreid · San Francisco, US
• Jiasheng Fu · Foster City, US
• Zhihong Li · San Jose, US
• Felix Gonzalez Lopez De Turiso · San Mateo, US
• Ana Z. Gonzalez Buenrostro · San Mateo, US
• Michael W. Gribble, Jr. · San Francisco, US
• Michael G. Johnson · San Diego, US
• Todd J. Kohn · Thousand Oaks, US
• Kexue Li · Newbury Park, US
• Yunxiao Li · Sunnyvale, US
• Mike Lizarzaburu · San Bruno, US
• Yosup Rew · Foster City, US
• Joshua Paul Gergely Taygerly · San Francisco, US
• Yingcai Wang · Millbrae, US
• Xuelei Yan · Foster City, US
• Ming Yu · Shaoxing, CN
• Jiang Zhu · San Ramon, US
• Manuel Zancanella · San Mateo, US
• Xian Yun Jiao · San Mateo, US
• Liusheng Zhu · Foster City, US
• Xianghong Wang · Dublin, US
• Julio C. Medina · Redwood City, US
• Jason A. Duquette · Millbrae, US
• Jonathan Houze · Cambridge, US
• Marc Vimolratana · New York, US
• Mario Cardozo · San Francisco, US
• Alan C. Cheng · Cambridge, US

Key dates

• Filing date: Feb 24, 2017
• Grant date: Apr 19, 2022
• Expiry date: Apr 18, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D515/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.